The Experts below are selected from a list of 31188 Experts worldwide ranked by ideXlab platform
Isabelle Leparc-goffart - One of the best experts on this subject based on the ideXlab platform.
-
Viscerotropic disease and acute uveitis following Yellow Fever vaccination: a case report
BMC Infectious Diseases, 2020Co-Authors: Lev Volkov, Gilda Grard, Pierre-edouard Bollaert, Guillaume Durand, Aurélie Cravoisy, Marie Conrad, Lionel Nace, Guilhem Courte, Rémy Marnai, Isabelle Leparc-goffartAbstract:BACKGROUND: Yellow Fever vaccine exists for over 80 years and is considered to be relatively safe. However, in rare cases it can produce serious neurotropic and viscerotropic complications. We report a case of a patient who presented both viscerotropic and neurological manifestations after Yellow Fever vaccination. CASE PRESENTATION: We describe the case of a 37 years old man who developed after the Yellow Fever vaccination a Yellow Fever vaccine-associated viscerotropic disease followed by acute uveitis. Prolonged detection of Yellow Fever RNA in blood and urine was consistent with Yellow Fever vaccine-associated adverse event. The final outcome was good, although with persistent fatigue over a few months. CONCLUSIONS: Even if the Yellow Fever vaccine is relatively safe, physicians should be aware of its possible serious adverse effects.
-
Viscerotropic disease and acute uveitis following Yellow Fever vaccination: a case report
BMC Infectious Diseases, 2020Co-Authors: Lev Volkov, Gilda Grard, Pierre-edouard Bollaert, Guillaume Durand, Aurélie Cravoisy, Marie Conrad, Lionel Nace, Guilhem Courte, Rémy Marnai, Isabelle Leparc-goffartAbstract:BACKGROUND: Yellow Fever vaccine exists for over 80 years and is considered to be relatively safe. However, in rare cases it can produce serious neurotropic and viscerotropic complications. We report a case of a patient who presented both viscerotropic and neurological manifestations after Yellow Fever vaccination. CASE PRESENTATION: We describe the case of a 37 years old man who developed after the Yellow Fever vaccination a Yellow Fever vaccine-associated viscerotropic disease followed by acute uveitis. Prolonged detection of Yellow Fever RNA in blood and urine was consistent with Yellow Fever vaccine-associated adverse event. The final outcome was good, although with persistent fatigue over a few months. CONCLUSIONS: Even if the Yellow Fever vaccine is relatively safe, physicians should be aware of its possible serious adverse effects.
Thomas P. Monath - One of the best experts on this subject based on the ideXlab platform.
-
Yellow Fever.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014Co-Authors: Thomas P. Monath, Pedro F C VasconcelosAbstract:Yellow Fever, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of Yellow Fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of Yellow Fever, with an emphasis on recent changes in the distribution and incidence of the disease. Recent knowledge about Yellow Fever 17D vaccine mechanism of action and safety are discussed.
-
The revised global Yellow Fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.
Lancet Infectious Diseases, 2011Co-Authors: Emily S. Jentes, J. Erin Staples, Annelies Wilder-smith, Oyewale Tomori, Mark D. Gershman, Gilles Poumerol, David R. Hill, Johan Lemarchand, Rosamund F Lewis, Thomas P. MonathAbstract:The changing epidemiology of Yellow Fever and continued reports of rare but serious adverse events associated with Yellow Fever vaccine have drawn attention to the need to revisit criteria for the designation of areas with risk for Yellow Fever virus activity, and to revise the vaccine recommendations for international travel. WHO convened a working group of international experts to review factors important for the transmission of Yellow Fever virus and country-specific Yellow Fever information, to establish criteria for additions to or removal from the list of countries with risk for Yellow Fever virus transmission, to update Yellow Fever risk maps, and to revise the recommendations for vaccination for international travel. This report details the recommendations made by the working group about criteria for the designation of risk and specific changes to the classification of areas with risk for transmission of Yellow Fever virus.
-
Yellow Fever
Oxford Medicine Online, 2011Co-Authors: Thomas P. Monath, J. Erin StaplesAbstract:Yellow Fever is an acute mosquito-borne flavivirus infection characterized in its full-blown form by Fever, jaundice, albuminuria, and haemorrhage. Two forms are distinguished: urban Yellow Fever in which the virus is spread from person to person by peridomestic Aedes aegypti mosquitoes and jungle (sylvan) Yellow Fever transmitted by tree-hole breeding mosquitoes between non-human primates and sometimes humans. Yellow Fever is endemic and epidemic in tropical areas of the Americas and Africa but has never appeared in Asia or the Pacific region. Prevention and control are effected principally through Yellow Fever vaccination.
-
Yellow Fever: 100 years of discovery.
JAMA, 2008Co-Authors: J. Erin Staples, Thomas P. MonathAbstract:The article describes a series of experiments conducted to explore how Yellow Fever is propagated from individual to individual and how the contagium is spread within households. The study was conducted in an experimental sanitary station in Cuba, where exposures and movements could be completely controlled. During the investigation, 12 nonimmune persons underwent different exposures, including mosquitoes that had fed on Yellow Fever patients, blood from infected patients, and fomites belonging to infected patients.The study provided the following observations: (1) Aedes aegypti mosquitoes transferred the disease from an infected individual to a nonimmune person; (2) at least 12 days were needed for the extrinsic incubation period in the mosquito before it could transmit the infection; (3) Yellow Fever can be transferred to a nonimmune person from the blood of an infected individual taken during the first 2 days of the illness; (4) a filterable agent was responsible for infection; (5) the incubation period for humans ranged between 2 and 6 days; and (6) Yellow Fever cannot be transmitted by fomites nor spread in a house without the presence of mosquitoes. The most significant conclusion was that the “spread of Yellow Fever can be most effectually controlled by measures directed to the destruction of mosquitoes.”See PDF for full text of the original JAMA article.
-
Yellow Fever Virus
Encyclopedia of Virology, 2008Co-Authors: Anthony A. Marfin, Thomas P. MonathAbstract:Yellow Fever virus is the prototype species of the Flaviviridae and the original ‘viral hemorrhagic Fever’ virus. Two biological properties, viscerotropism and neurotropism are inherent to all wild-type Yellow Fever virus strains, and are frequently associated with profound shock and the systemic inflammatory response syndrome (SIRS), likely mediated by pro-inflammatory cytokines and cytokine dysregulation. Humans and nonhuman primates are the amplifying hosts in all three of the transmission cycles. Although Aedes aegypti is the vector during large peridomestic human-to-human Yellow Fever outbreaks, other Aedes spp. play a role in zoonotic transmission in the sylvatic and savanna transmission cycles. Domestic control of Ae. aegypti has been an important disease-control method but is difficult to sustain. Currently, the most effective control strategy is to immunize persons living and traveling in endemic areas with 17D vaccine, a live attenuated vaccine.
Marleen Boelaert - One of the best experts on this subject based on the ideXlab platform.
-
Urbanisation of Yellow Fever in Santa Cruz Bolivia.
The Lancet, 1999Co-Authors: P. Van Der Stuyft, A Gianella, M Pirard, Jl Céspedes, J Lora, C Peredo, José Luis Pelegrino, V Vorndam, Marleen BoelaertAbstract:Summary Background Reinvasion by Aedes aegypti of cities in the Americas poses a threat of urbanisation of Yellow Fever. After detection of Yellow-Fever infection in a resident of the city of Santa Cruz, Bolivia, in December, 1997, we investigated all subsequent suspected cases. Methods We introduced active surveillance of Yellow Fever in the Santa Cruz area. Hospitals and selected urban and rural health centres reported all suspected cases. Patients were serologically screened for Yellow Fever, dengue, hepatitis A and B, and leptospirosis. We collected clinical and epidemiological information from patients' records and through interviews. We also carried out a population-based serosurvey in the neighbourhood of one case. Fndings Between December, 1997, and June, 1998, symptomatic Yellow-Fever infection was confirmed in six residents of Santa Cruz, five of whom died. Five lived in the southern sector of the city. Two had not left the city during the incubation period, and one had visited only an area in which sylvatic transmission was deemed impossible. Of the 281 people covered in the serosurvey 16 (6%) were positive for IgM antibody to Yellow Fever. Among five people for whom this result could not be explained by recent vaccination, there were two pairs of neighbours. Interpretation Urban transmission of Yellow Fever in Santa Cruz was limited in space and time. Low Yellow-Fever immunisation coverage and high infestation with A aegypti in the city, and the existence of endemic areas in the region present a risk for future urban outbreaks. We recommend immediate large-scale immunisation of the urban population, as well as tightened surveillance and appropriate vector control.
-
urbanisation of Yellow Fever in santa cr uz bolivia
The Lancet, 1999Co-Authors: P Van Der Stuyft, A Gianella, M Pirard, Jl Céspedes, J Lora, C Peredo, José Luis Pelegrino, V Vorndam, Marleen BoelaertAbstract:Summary Background Reinvasion by Aedes aegypti of cities in the Americas poses a threat of urbanisation of Yellow Fever. After detection of Yellow-Fever infection in a resident of the city of Santa Cruz, Bolivia, in December, 1997, we investigated all subsequent suspected cases. Methods We introduced active surveillance of Yellow Fever in the Santa Cruz area. Hospitals and selected urban and rural health centres reported all suspected cases. Patients were serologically screened for Yellow Fever, dengue, hepatitis A and B, and leptospirosis. We collected clinical and epidemiological information from patients' records and through interviews. We also carried out a population-based serosurvey in the neighbourhood of one case. Fndings Between December, 1997, and June, 1998, symptomatic Yellow-Fever infection was confirmed in six residents of Santa Cruz, five of whom died. Five lived in the southern sector of the city. Two had not left the city during the incubation period, and one had visited only an area in which sylvatic transmission was deemed impossible. Of the 281 people covered in the serosurvey 16 (6%) were positive for IgM antibody to Yellow Fever. Among five people for whom this result could not be explained by recent vaccination, there were two pairs of neighbours. Interpretation Urban transmission of Yellow Fever in Santa Cruz was limited in space and time. Low Yellow-Fever immunisation coverage and high infestation with A aegypti in the city, and the existence of endemic areas in the region present a risk for future urban outbreaks. We recommend immediate large-scale immunisation of the urban population, as well as tightened surveillance and appropriate vector control.
Lev Volkov - One of the best experts on this subject based on the ideXlab platform.
-
Viscerotropic disease and acute uveitis following Yellow Fever vaccination: a case report
BMC Infectious Diseases, 2020Co-Authors: Lev Volkov, Gilda Grard, Pierre-edouard Bollaert, Guillaume Durand, Aurélie Cravoisy, Marie Conrad, Lionel Nace, Guilhem Courte, Rémy Marnai, Isabelle Leparc-goffartAbstract:BACKGROUND: Yellow Fever vaccine exists for over 80 years and is considered to be relatively safe. However, in rare cases it can produce serious neurotropic and viscerotropic complications. We report a case of a patient who presented both viscerotropic and neurological manifestations after Yellow Fever vaccination. CASE PRESENTATION: We describe the case of a 37 years old man who developed after the Yellow Fever vaccination a Yellow Fever vaccine-associated viscerotropic disease followed by acute uveitis. Prolonged detection of Yellow Fever RNA in blood and urine was consistent with Yellow Fever vaccine-associated adverse event. The final outcome was good, although with persistent fatigue over a few months. CONCLUSIONS: Even if the Yellow Fever vaccine is relatively safe, physicians should be aware of its possible serious adverse effects.
-
Viscerotropic disease and acute uveitis following Yellow Fever vaccination: a case report
BMC Infectious Diseases, 2020Co-Authors: Lev Volkov, Gilda Grard, Pierre-edouard Bollaert, Guillaume Durand, Aurélie Cravoisy, Marie Conrad, Lionel Nace, Guilhem Courte, Rémy Marnai, Isabelle Leparc-goffartAbstract:BACKGROUND: Yellow Fever vaccine exists for over 80 years and is considered to be relatively safe. However, in rare cases it can produce serious neurotropic and viscerotropic complications. We report a case of a patient who presented both viscerotropic and neurological manifestations after Yellow Fever vaccination. CASE PRESENTATION: We describe the case of a 37 years old man who developed after the Yellow Fever vaccination a Yellow Fever vaccine-associated viscerotropic disease followed by acute uveitis. Prolonged detection of Yellow Fever RNA in blood and urine was consistent with Yellow Fever vaccine-associated adverse event. The final outcome was good, although with persistent fatigue over a few months. CONCLUSIONS: Even if the Yellow Fever vaccine is relatively safe, physicians should be aware of its possible serious adverse effects.
P Van Der Stuyft - One of the best experts on this subject based on the ideXlab platform.
-
urbanisation of Yellow Fever in santa cr uz bolivia
The Lancet, 1999Co-Authors: P Van Der Stuyft, A Gianella, M Pirard, Jl Céspedes, J Lora, C Peredo, José Luis Pelegrino, V Vorndam, Marleen BoelaertAbstract:Summary Background Reinvasion by Aedes aegypti of cities in the Americas poses a threat of urbanisation of Yellow Fever. After detection of Yellow-Fever infection in a resident of the city of Santa Cruz, Bolivia, in December, 1997, we investigated all subsequent suspected cases. Methods We introduced active surveillance of Yellow Fever in the Santa Cruz area. Hospitals and selected urban and rural health centres reported all suspected cases. Patients were serologically screened for Yellow Fever, dengue, hepatitis A and B, and leptospirosis. We collected clinical and epidemiological information from patients' records and through interviews. We also carried out a population-based serosurvey in the neighbourhood of one case. Fndings Between December, 1997, and June, 1998, symptomatic Yellow-Fever infection was confirmed in six residents of Santa Cruz, five of whom died. Five lived in the southern sector of the city. Two had not left the city during the incubation period, and one had visited only an area in which sylvatic transmission was deemed impossible. Of the 281 people covered in the serosurvey 16 (6%) were positive for IgM antibody to Yellow Fever. Among five people for whom this result could not be explained by recent vaccination, there were two pairs of neighbours. Interpretation Urban transmission of Yellow Fever in Santa Cruz was limited in space and time. Low Yellow-Fever immunisation coverage and high infestation with A aegypti in the city, and the existence of endemic areas in the region present a risk for future urban outbreaks. We recommend immediate large-scale immunisation of the urban population, as well as tightened surveillance and appropriate vector control.
